Transcatheter aortic valve replacement (TAVR) is a rising alternative to surgical aortic valve replacement (SAVR) in otherwise inoperable or high-risk patients with severe aortic stenosis. Its penetration into aortic valve replacement is growing fast, extending to younger and lower-risk patients, and Morgan Stanley recently predicted a $7.4 billion TAVR market by 2025. Like other left-sided heart procedures, TAVR carries a stroke risk because debris can be released into the aorta as the new valve is placed. (See[A#2014700132]and Also see "TAVR Market: Next-Generation Devices Seek To Optimize Outcomes" - Medtech Insight, 28 March, 2014..)
Although results from the ADVANCE study published in the July 21, 2015, issue of the Journal of the American College of Cardiology (JACC) suggest TAVR stroke rates are diminishing, stroke...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?